These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 12552250

  • 1. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
    Niller HH, Salamon D, Ilg K, Koroknai A, Banati F, Bauml G, Rucker O, Schwarzmann F, Wolf H, Minarovits J.
    Med Sci Monit; 2003 Jan; 9(1):HY1-9. PubMed ID: 12552250
    [Abstract] [Full Text] [Related]

  • 2. The Epstein-Barr virus BRLF1 gene product transactivates the murine and human c-myc promoters.
    Gutsch DE, Marcu KB, Kenney SC.
    Cell Mol Biol (Noisy-le-grand); 1994 Sep; 40(6):747-60. PubMed ID: 7812182
    [Abstract] [Full Text] [Related]

  • 3. The LCR of EBV makes Burkitt's lymphoma endemic.
    Niller HH, Salamon D, Banati F, Schwarzmann F, Wolf H, Minarovits J.
    Trends Microbiol; 2004 Nov; 12(11):495-9. PubMed ID: 15488390
    [Abstract] [Full Text] [Related]

  • 4. [Epstein-Barr virus and Burkitt's lymphoma].
    Joab I.
    Med Trop (Mars); 1999 Nov; 59(4 Pt 2):499-502. PubMed ID: 10901854
    [Abstract] [Full Text] [Related]

  • 5. [Molecular pathological characteristics of human B-cell lymphomas induced by Epstein-Barr virus].
    Gan RL, Yin ZH, Liu TF, Dong BH, Zhou JG, Yao KT.
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):925-9. PubMed ID: 14515211
    [Abstract] [Full Text] [Related]

  • 6. Epstein-Barr virus and Burkitt's lymphoma.
    Magrath I, Jain V, Bhatia K.
    Semin Cancer Biol; 1992 Oct; 3(5):285-95. PubMed ID: 1335792
    [Abstract] [Full Text] [Related]

  • 7. Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression.
    Wolf J, Pawlita M, Bullerdiek J, zur Hausen H.
    Cancer Res; 1990 May 15; 50(10):3095-100. PubMed ID: 2159373
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
    Jochner N, Eick D, Zimber-Strobl U, Pawlita M, Bornkamm GW, Kempkes B.
    EMBO J; 1996 Jan 15; 15(2):375-82. PubMed ID: 8617212
    [Abstract] [Full Text] [Related]

  • 10. Replacement of the Epstein-Barr virus plasmid with the EBER plasmid in Burkitt's lymphoma cells.
    Maruo S, Nanbo A, Takada K.
    J Virol; 2001 Oct 15; 75(20):9977-82. PubMed ID: 11559830
    [Abstract] [Full Text] [Related]

  • 11. EBV-associated neoplasms: alternative pathogenetic pathways.
    Niller HH, Salamon D, Ilg K, Koroknai A, Banati F, Schwarzmann F, Wolf H, Minarovits J.
    Med Hypotheses; 2004 Oct 15; 62(3):387-91. PubMed ID: 14975509
    [Abstract] [Full Text] [Related]

  • 12. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
    Strobl LJ, Kohlhuber F, Mautner J, Polack A, Eick D.
    Oncogene; 1993 Jun 15; 8(6):1437-47. PubMed ID: 8502472
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cell phenotype-dependent splicing reflecting differential promoter usage for EBNA transcripts in EBV-carrying cells.
    Hu LF, Chen F, Altiok E, Winberg G, Klein G, Ernberg I.
    Gan To Kagaku Ryoho; 2000 May 15; 27 Suppl 2():248-60. PubMed ID: 10895161
    [Abstract] [Full Text] [Related]

  • 15. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
    Staege MS, Lee SP, Frisan T, Mautner J, Scholz S, Pajic A, Rickinson AB, Masucci MG, Polack A, Bornkamm GW.
    Proc Natl Acad Sci U S A; 2002 Apr 02; 99(7):4550-5. PubMed ID: 11917131
    [Abstract] [Full Text] [Related]

  • 16. c-MYC impairs immunogenicity of human B cells.
    Schlee M, Schuhmacher M, Hölzel M, Laux G, Bornkamm GW.
    Adv Cancer Res; 2007 Apr 02; 97():167-88. PubMed ID: 17419945
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Epstein-Barr virus-infected marmoset cells transfected with c-myc do not form lymphomas in mice with severe combined immunodeficiency.
    Salimi B, O'Gorman MR, Variakojis D, Bendet M, Newman M, Poupko E, Katz BZ.
    Mol Genet Metab; 1998 Jul 02; 64(3):205-12. PubMed ID: 9719630
    [Abstract] [Full Text] [Related]

  • 19. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
    Sandlund JT, Neckers LM, Schneller HE, Woodruff LS, Magrath IT.
    Cancer Res; 1993 Jan 01; 53(1):127-32. PubMed ID: 8416737
    [Abstract] [Full Text] [Related]

  • 20. Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma.
    Arcinas M, Heckman CA, Mehew JW, Boxer LM.
    Cancer Res; 2001 Jul 01; 61(13):5202-6. PubMed ID: 11431360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.